drugset / Trial / NCT05824767

Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock

NCT05824767

RandomizedParallel-groupOpen-labelTreatment

Summary

This trial will be a randomized controlled single-center pilot trial comparing the use of angiotensin II versus standard-of-care (SOC) vasopressor therapy in adult patients with persistent vasodilatory shock despite moderate-dose norepinephrine, with a primary outcome of the ability of novel biomarkers (renin and DPP3) to predict blood pressure response to angiotensin II. Given our angiotensin II will be compared to SOC, this will be an unblinded study.

Timeline

Start
2023-04-17
Primary completion
2025-03-12
Completion
2025-03-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Angiotensin II Peptide 20 ng/ml